On November 20, 2023, WestVac BioPharma’s Recombinant COVID-19 Trivalent XBB Protein Vaccine(Sf9 Cell)-Coviccine® Trivalent XBB Vaccine has been launched nationwide. It is reported that the Coviccine® Trivalent XBB Vaccine has already been shipped and will gradually arrive at multiple national disease control centers and vaccination units. People who are eligible for vaccination can consult with the relevant disease control centers and vaccination units to make an appointment for vaccination.
In July 2023, the "Work Plan for COVID-19 Vaccination of Key Populations in the Near Future" (hereinafter referred to as the "Vaccination Plan") was issued according to the Joint Prevention and Control Mechanism of the State Council for COVID-19. The Vaccination Plan clearly states that during the prevalence of the XBB variant of COVID-19, especially during the autumn and winter of this year, vaccination with vaccines containing XBB variant antigens is prioritized. the Recombinant COVID-19 Trivalent XBB Protein Vaccine (Sf9 Cell) developed by WestVac BioPharma was recommended preferential and has now been included in emergency use within a certain scope and can be used for vaccination of designated key populations in the near term.
WestVac BioPharma Co., Ltd. is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales. Coviccine® Trivalent XBB Vaccine is a high-purity and high-quality recombinant trivalent vaccine against COVID-19 variants produced by WestVac BioPharma by taking advantage of the rapid response of the internationally advanced insect cell-based recombinant protein vaccine production technology platform and completing the construction of the vector in a highly efficient manner. The vaccine, targeting the receptor-binding domain (RBD) and heptad repeat (HR) domain of the spike protein of the XBB and other variants of COVID-19, develops subunit vaccine antigens that self-assemble into stable trimeric protein particles based on precise structure design. These particles are purified, mixed, and then combined with an oil-in-water emulsion adjuvant based on squalene. This innovative adjuvant significantly enhances the vaccine's neutralizing antibody titers and induces a stronger T-cell immune response in the body.
Clinical trial data showed that the Coviccine® Trivalent XBB Vaccine can induce high levels of neutralizing antibodies against XBB.1, XBB.1.5, XBB.1.16, XBB.1.9.1, EG.5, XBB.2.3, BA.5 and other variants, with good safety, and is of great significance for preventing variant infections, reducing severe cases, and lowering mortality rates.
